Cecilia G Ethun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4468349/publications.pdf

Version: 2024-02-01

81 papers

2,193 citations

218381 26 h-index 253896 43 g-index

81 all docs

81 docs citations

times ranked

81

3249 citing authors

#	Article	IF	CITATIONS
1	Perioperative Versus Adjuvant Chemotherapy in the Management of Incidentally Found Gallbladder Cancer (OPT-IN). Annals of Surgical Oncology, 2022, 29, 37-38.	0.7	5
2	Impact of resection margin on outcomes in highâ€grade soft tissue sarcomas of the extremity—A USSC analysis. Journal of Surgical Oncology, 2021, 123, 479-488.	0.8	3
3	Renal Function After Retroperitoneal Sarcoma Resection with Nephrectomy: A Matched Analysis of the United States Sarcoma Collaborative Database. Annals of Surgical Oncology, 2021, 28, 1690-1696.	0.7	9
4	Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer. Annals of Surgical Oncology, 2021, 28, 417-425.	0.7	21
5	Outcomes in Patients with Renal Cell Carcinoma Undergoing Inferior Vena Cava Ligation without Reconstruction versus Thrombectomy: A Retrospective, Case Controlled Study. Journal of Urology, 2021, 205, 383-391.	0.2	8
6	Defining the Risk of Early Recurrence Following Curative-Intent Resection for Distal Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 4205-4213.	0.7	19
7	A multiâ€institutional validation study of prognostic nomograms for retroperitoneal sarcoma. Journal of Surgical Oncology, 2021, 124, 829-837.	0.8	9
8	A novel preoperative risk score to guide patient selection for resection of soft tissue sarcoma lung metastases: An analysis from the United States Sarcoma Collaborative. Journal of Surgical Oncology, 2021, 124, 1477-1484.	0.8	7
9	STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?. Journal of Gastrointestinal Surgery, 2020, 24, 1138-1148.	0.9	5
10	Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas. Journal of Surgical Research, 2020, 245, 577-586.	0.8	3
11	Is a Nomogram Able to Predict Postoperative Wound Complications in Localized Soft-tissue Sarcomas of the Extremity?. Clinical Orthopaedics and Related Research, 2020, 478, 550-559.	0.7	10
12	Analysis of textbook outcomes among patients undergoing resection of retroperitoneal sarcoma: A multiâ€institutional analysis of the US Sarcoma Collaborative. Journal of Surgical Oncology, 2020, 122, 1189-1198.	0.8	19
13	High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. Surgery, 2020, 168, 760-767.	1.0	2
14	HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target. Surgical Oncology, 2020, 35, 460-465.	0.8	1
15	A closer look at the natural history and recurrence patterns of high-grade truncal/extremity leiomyosarcomas: A multi-institutional analysis from the US Sarcoma Collaborative. Surgical Oncology, 2020, 34, 292-297.	0.8	2
16	Retroperitoneal sarcoma perioperative risk stratification: A United States Sarcoma Collaborative evaluation of the ACSâ€NSQIP risk calculator. Journal of Surgical Oncology, 2020, 122, 795-802.	0.8	4
17	Outcomes of palliativeâ€intent surgery in retroperitoneal sarcoma—Results from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2020, 121, 1140-1147.	0.8	7
18	Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas: Analysis From the US Sarcoma Collaborative. Journal of Surgical Research, 2019, 233, 154-162.	0.8	6

#	Article	lF	CITATIONS
19	Lung Surveillance Strategy for High-Grade Soft Tissue Sarcomas: Chest X-Ray or CT Scan?. Journal of the American College of Surgeons, 2019, 229, 449-457.	0.2	14
20	Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. Annals of Surgical Oncology, 2019, 26, 3542-3549.	0.7	19
21	Recurrence patterns after resection of retroperitoneal sarcomas: An eightâ€institution study from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 340-347.	0.8	29
22	Role of radiation therapy for retroperitoneal sarcomas: An eightâ€institution study from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 1227-1234.	0.8	26
23	The Prognostic Value of Lymphovascular Invasion in Truncal and Extremity Soft Tissue Sarcomas: An Analysis from the National Cancer Database. Annals of Surgical Oncology, 2019, 26, 4723-4729.	0.7	9
24	The impact of unplanned excisions of truncal/extremity soft tissue sarcomas: A multiâ€institutional propensity score analysis from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 332-339.	0.8	25
25	The role of radiation therapy and margin width in localized softâ€tissue sarcoma: Analysis from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 325-331.	0.8	16
26	The conundrum of < 2-cm pancreatic neuroendocrine tumors: AÂpreoperative risk score to predict lymph node metastases and guide surgical management. Surgery, 2019, 166, 15-21.	1.0	34
27	Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2019, 26, 1814-1823.	0.7	19
28	Staging laparoscopy among three subtypes of extraâ€hepatic biliary malignancy: a 15â€year experience from 10 institutions. Journal of Surgical Oncology, 2019, 119, 288-294.	0.8	12
29	Identifying the barriers to gastric cancer care at safetyâ€net hospitals: A novel comparison of a safetyâ€net hospital to a neighboring quaternary referral academic center in the same healthcare system. Journal of Surgical Oncology, 2019, 119, 64-70.	0.8	9
30	Actual 5-Year Survivors After Surgical Resection of Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 611-618.	0.7	34
31	Evaluation and management of incidental gallbladder cancer. Chinese Clinical Oncology, 2019, 8, 37-37.	0.4	13
32	The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2018, 25, 1140-1149.	0.7	48
33	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. Annals of Surgical Oncology, 2018, 25, 520-527.	0.7	15
34	Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. European Journal of Surgical Oncology, 2018, 44, 810-815.	0.5	28
35	Defining Early Recurrence of Hilar Cholangiocarcinoma After Curativeâ€intent Surgery: A Multiâ€institutional Study from the US Extrahepatic Biliary Malignancy Consortium. World Journal of Surgery, 2018, 42, 2919-2929.	0.8	48
36	Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. Hpb, 2018, 20, 332-339.	0.1	27

#	Article	IF	CITATIONS
37	The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium. Surgery, 2018, 163, 726-731.	1.0	29
38	Transplantation Versus Resection for Hilar Cholangiocarcinoma. Annals of Surgery, 2018, 267, 797-805.	2.1	137
39	Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease. Annals of Surgical Oncology, 2018, 25, 290-298.	0.7	15
40	Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: Percutaneous biliary drainage has no adverse effects on survival. Journal of Surgical Oncology, 2018, 117, 1267-1277.	0.8	32
41	<i>Colon and Rectal Neuroendocrine Tumors: Are They Really One Disease? A Single-Institution Experience over 15 Years</i> i>. American Surgeon, 2018, 84, 717-726.	0.4	9
42	ASO Author Reflections: Incorporating Lymphovascular Invasion to Improve the Prognostic Reliability of the T-Staging System for Adrenocortical Carcinoma—A Multicenter Study. Annals of Surgical Oncology, 2018, 25, 862-863.	0.7	0
43	A novel, simplified, externally validated staging system for truncal/extremity soft tissue sarcomas: An analysis of the US Sarcoma Collaborative database. Journal of Surgical Oncology, 2018, 118, 1135-1141.	0.8	4
44	The value of a crossâ€discipline teamâ€based approach for resection of renal cell carcinoma with IVC tumor thrombus: A report of a large, contemporary, singleâ€institution experience. Journal of Surgical Oncology, 2018, 118, 1219-1226.	0.8	18
45	<i>The Hand-Assisted Laparoscopic Approach to Resection of Pancreatic Mucinous Cystic Neoplasms: An Underused Technique?</i> An Underused Technique? 	0.4	3
46	Association of perioperative transfusion with survival and recurrence after resection of gallbladder cancer: A 10â€institution study from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology, 2018, 117, 1638-1647.	0.8	10
47	Perioperative chemotherapy is not associated with improved survival in high-grade truncal sarcoma. Journal of Surgical Research, 2018, 231, 248-256.	0.8	2
48	Studying a Rare Disease Using Multi-Institutional Research Collaborations vs Big Data: Where Lies the Truth?. Journal of the American College of Surgeons, 2018, 227, 357-366e3.	0.2	13
49	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group. VideoEndocrinology, 2018, 5, .	0.1	0
50	The diagnosis of pancreatic mucinous cystic neoplasm and associated adenocarcinoma in males: An eightâ€institution study of 349 patients over 15 years. Journal of Surgical Oncology, 2017, 115, 784-787.	0.8	15
51	Routine portâ€site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multiâ€institution analysis from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology, 2017, 115, 805-811.	0.8	28
52	Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?. Journal of Gastrointestinal Surgery, 2017, 21, 1245-1253.	0.9	30
53	Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium. Journal of the American College of Surgeons, 2017, 224, 406-413.	0.2	28
54	Evaluating the American College of Surgeons National Surgical Quality Improvement project risk calculator: results from the U.S. Extrahepatic Biliary Malignancy Consortium. Hpb, 2017, 19, 1104-1111.	0.1	25

#	Article	IF	Citations
55	The Oncologic Impact of Postoperative Complications Following Resection of Truncal and Extremity Soft Tissue Sarcomas. Annals of Surgical Oncology, 2017, 24, 3574-3586.	0.7	11
56	Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. Ca-A Cancer Journal for Clinicians, 2017, 67, 362-377.	157.7	364
57	Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience. Annals of Surgical Oncology, 2017, 24, 2770-2776.	0.7	25
58	A Novel Pathology-Based Preoperative Risk Score to Predict Locoregional Residual and Distant Disease and Survival for Incidental Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2017, 24, 1343-1350.	0.7	68
59	Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms. JAMA Surgery, 2017, 152, 19.	2.2	82
60	Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival. JAMA Surgery, 2017, 152, 143.	2.2	74
61	Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer. World Journal of Surgery, 2017, 41, 224-231.	0.8	19
62	Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. American Surgeon, 2017, 83, 679-686.	0.4	44
63	Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group. American Surgeon, 2017, 83, 761-768.	0.4	12
64	Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy. Journal of Surgical Oncology, 2016, 114, 440-445.	0.8	47
65	Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer. Journal of Surgical Oncology, 2016, 114, 176-180.	0.8	30
66	The importance of surgical margins in pancreatic cancer. Journal of Surgical Oncology, 2016, 113, 283-288.	0.8	49
67	Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years. Journal of Surgical Oncology, 2016, 114, 163-169.	0.8	6
68	The importance of surgical margins in melanoma. Journal of Surgical Oncology, 2016, 113, 339-345.	0.8	32
69	Determination of Resectability. Surgical Clinics of North America, 2016, 96, 163-181.	0.5	10
70	Prognostic Implications of Lymph Node Status for Patients With Gallbladder Cancer: A Multi-Institutional Study. Annals of Surgical Oncology, 2016, 23, 3016-3023.	0.7	42
71	Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. Journal of the American College of Surgeons, 2016, 222, 750-759e2.	0.2	61
72	Proposal for a new T-stage classification system for distal cholangiocarcinoma: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 793-799.	0.1	17

#	Article	IF	Citations
73	Elevated NLR in gallbladder cancer and cholangiocarcinoma – making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. Hpb, 2016, 18, 950-957.	0.1	50
74	Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. Journal of Surgical Oncology, 2016, 114, 336-341.	0.8	8
75	Small bowel neuroendocrine tumors: A critical analysis of diagnostic workâ€up and operative approach. Journal of Surgical Oncology, 2016, 114, 671-676.	0.8	29
76	A 15-year experience with gastric neuroendocrine tumors: Does type make a difference?. Journal of Surgical Oncology, 2016, 114, 576-580.	0.8	19
77	Assessing Trends in Palliative Surgery for Extrahepatic Biliary Malignancies: A 15-Year Multicenter Study. Journal of Gastrointestinal Surgery, 2016, 20, 1444-1452.	0.9	16
78	Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. Annals of Surgical Oncology, 2016, 23, 2998-3008.	0.7	44
79	Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. Journal of the American College of Surgeons, 2016, 222, 480-490.	0.2	71
80	Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years Journal of Clinical Oncology, 2016, 34, 228-228.	0.8	0
81	A multi-center study of 349 pancreatic mucinous cystic neoplasms: Preoperative risk factors for adenocarcinoma Journal of Clinical Oncology, 2016, 34, 231-231.	0.8	O